A
Aleta Biotherapeutics
Immuno-oncology company focused on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted
About Aleta Biotherapeutics
Aleta Biotherapeutics is a clinical-stage immuno-oncology firm established in 2015 by co-founders Paul Rennert and Roy Lobb, who contribute significant experience in immunology, oncology, and drug development. The company operates as a privately-held entity, having secured $17.3 million in funding from investors including Advent Life Sciences, Columbus Venture Partners, and ABI LAB. The business is focused on developing therapies to improve the outcomes for cancer patients undergoing cell therapy.
The company's core technology platform, CAR-T Engager (CTE), develops off-the-shelf biologic therapies designed to work with CAR T-cell treatments. Aleta's approach addresses a critical challenge in CAR T-cell therapy: patient relapse, which often occurs due to the cancer cells reducing or losing the target antigen, like CD19, that the therapy is designed to recognize. Aleta's CTEs are engineered proteins that bind to a different, more stable antigen on the cancer cell and simultaneously present the original target, effectively 'recoating' the tumor cell. This action restores the ability of the patient's existing, circulating CAR T-cells to recognize and attack the cancer, aiming to create deeper and more durable responses.
Aleta's lead program, ALETA-001, is designed for patients with B-cell malignancies who have relapsed after or are refractory to CD19-directed CAR T-cell therapy. This CTE binds to the CD20 antigen on cancer cells and presents the CD19 protein, making the cancer visible again to anti-CD19 CAR T-cells. In a significant milestone, Aleta partnered with Cancer Research UK in June 2021, with the latter agreeing to fund, sponsor, and conduct the first-in-human Phase 1/2a clinical trial for ALETA-001. This trial, which received Clinical Trial Authorisation from the UK's MHRA in August 2023, began dosing its first patients in February 2024. Aleta retains the rights for further development and commercialization, with Cancer Research UK receiving success-based milestones and royalties. The company is also expanding its CTE platform to target solid tumors, including breast and gastric cancers, as well as other hematologic malignancies like acute myeloid leukemia (AML) and multiple myeloma.
Source: Dealroom company dataNews
Open roles
Aleta Biotherapeutics in the Natick ecosystem
The Aleta Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Advent Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aleta Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aleta Biotherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


